• When Is CAR T-Cell Therapy the Answer?

  • 2023/05/11
  • 再生時間: 21 分
  • ポッドキャスト

When Is CAR T-Cell Therapy the Answer?

  • サマリー

  • Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what's next in this rapidly advancing field.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL https://pubmed.ncbi.nlm.nih.gov/36045296/

    Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/30586620/

    Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes https://pubmed.ncbi.nlm.nih.gov/32750704/

    A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/33670075/

    CAR T-cell Therapy for B-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35012754/

    Current State and Next-Generation CAR-T Cells in Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35131139/

    Rapid Manufacturing of Non-activated Potent CAR T Cells https://pubmed.ncbi.nlm.nih.gov/35190680/

    続きを読む 一部表示

あらすじ・解説

Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what's next in this rapidly advancing field.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL https://pubmed.ncbi.nlm.nih.gov/36045296/

Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/30586620/

Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes https://pubmed.ncbi.nlm.nih.gov/32750704/

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/33670075/

CAR T-cell Therapy for B-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35012754/

Current State and Next-Generation CAR-T Cells in Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35131139/

Rapid Manufacturing of Non-activated Potent CAR T Cells https://pubmed.ncbi.nlm.nih.gov/35190680/

When Is CAR T-Cell Therapy the Answer?に寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。